Treatment Landscape of Late-Stage Metastatic EGFR-Positive NSCLC, Side Effect Education, and Shared Decision-Making

Dr. Konduri provides an overview of the current frontline treatment landscape for metastatic EGFR-positive NSCLC. Targeted therapies are the cornerstone, including the tyrosine kinase inhibitor osimertinib as monotherapy, osimertinib in combination with chemotherapy, and the combination of the bispecific antibody amivantamab with the tyrosine kinase inhibitor lazertinib. Immunotherapy plays a limited role in frontline EGFR-positive disease but is a major therapeutic modality across the broader NSCLC population.

Elizabeth Dennis outlines the side effect profile common to these agents. Dermatologic toxicities such as rashes, hand-foot reactions require proactive management with ceramide-based moisturizers, chlorhexidine rinses, sun-protective clothing, and sun protection factor products. Diarrhea should be managed at home with loperamide, with specific thresholds for calling the clinic, typically 4 to 6 episodes per day. Nausea requires rotation of antiemetic medications and prompt reporting if it impairs hydration or nutrition. Important red-flag symptoms requiring immediate reporting include sudden vision changes, new or worsening shortness of breath, palpitations, weight gain of 5 pounds in one day or 10 pounds in 1 week, extremity swelling, or chest pain, any of which may signal blood clots, cardiac arrhythmias, or pericardial effusion. Interstitial lung disease, a rare but serious complication, requires vigilance for new or worsening cough, shortness of breath, or increased oxygen requirements.

Lynn Abbott-McCloud describes advocacy group discussions about treatment, noting that many patients are surprised to learn the full range of their options, and that the distinction between informed decision-making and shared decision-making is an active focus of LiveLung's education efforts. Peer conversation at group meetings, where patients share experiences with specific medications, is a uniquely powerful educational tool that complements formal medical education.

Regarding frontline treatment selection between monotherapy and combination approaches, Elizabeth Dennis explains that combination therapies may offer superior disease control, whereas monotherapy may provide sufficient benefit with a lower treatment burden. Patient frailty, comorbidities, and performance status all influence the decision, and the patient must be educated and actively involved in this choice.